Relationship between respiratory syncytial virus bronchiolitis and future obstructive airway diseases

European Respiratory Journal

Volumn 18, Issue 6, 2001, Pages 1044-1058

  Wennergren, G ^a   Kristjansson S ^a  

^a QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

Author keywords

Allergy; Asthma; Bronchiolitis; Infant; Outcome; Respiratory syncytial virus

Indexed keywords

ADRENALIN; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CYTOKINE; LUNG SURFACTANT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PALIVIZUMAB; PLACEBO; PREDNISOLONE; RIBAVIRIN; SALBUTAMOL; VIRUS VACCINE;

ALLERGIC REACTION; ANIMAL EXPERIMENT; ARTICLE; ATOPY; BRONCHIOLITIS; CHILD; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; HUMAN; INFANT; INFECTION RISK; LONG TERM CARE; MORBIDITY; NONHUMAN; OBSTRUCTIVE AIRWAY DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK ASSESSMENT; RISK FACTOR; SENSITIZATION; VIRUS INFECTION; WHEEZING;

AIRWAY OBSTRUCTION; ANTIBODIES, VIRAL; ANTIBODY FORMATION; BRONCHIOLITIS; HUMANS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 0035691718     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.01.00254101     Document Type: Article

References (108)

1. The role of viral infections in the natural history of asthma
2. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7
3. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years
4. Respiratory syncytial virus infection
5. Respiratory syncytial virus: A continuing culprit and conundrum
6. Recovery of cytopathogenic agent from chimpanzees with coryza
7. Viruses and asthma
8. Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection
9. The etiologic and epidemiologic spectrum of bronchiolitis in pediatric practice
10. Incidence of respiratory syncytial and parainfluenza type 3 viruses in an urban setting
11. Respiratory syncytial virus and parainfluenza viruses
12. Efficacy of bronchodilators in the treatment of bronchiolitis
13. Efficacy of bronchodilator therapy in bronchiolitis. A meta-analysis
14. Nebulised racemic adrenaline in the treatment of acute bronchiolitis in infants and toddlers
15. Effect of racemic epinephrine and salbutamol on clinical score and pulmonary mechanics in infants with bronchiolitis
16. A randomized trial comparing the efficacy of epinephrine with salbutamol in the treatment of acute bronchiolitis
17. The clinical efficacy of nebulized racemic epinephrine and albuterol in acute bronchiolitis
18. Efficacy of nebulized epinephrine versus salbutamol in hospitalised infants with bronchiolitis
19. Early nebulized budesonide in the treatment of bronchiolitis and prevention of postbronchiolitic wheezing
20. Prednisolone treatment of respiratory syncytial virus infection: A randomized controlled trial of 147 infants
21. Respiratory syncytial virus bronchiolitis: A double blind dexamethasone efficacy study
22. Dexamethasone in bronchiolitis: A randomised controlled trial
23. Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis
24. Randomised double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis
25. Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview
26. Eosinophil cationic protein in nasopharyngeal secretions and serum of infants infected with respiratory syncytial virus
27. Inflammatory responses in respiratory syncytial virus infection in infants; Cytokines, chemokines and eosinophil cationic protein
28. The release of leukotrienes in the respiratory tract during infection with respiratory syncytial virus: Role in obstructive airway disease
29. Increased production of IFN-gamma and cysteinyl leukotrienes in virus-induced wheezing
30. Neural control mechanisms within airways: Disruption by respiratory syncytial virus
31. RSV and reactive airway disease: Is there an association?
32. Respiratory syncytial virus upregulates expression of the substance P receptor in rat lungs
33. Persistence of respiratory syncytial virus genome and protein after acute bronchiolitis in guinea pigs
34. Mechanisms of airway narrowing and hyperresponsiveness in viral respiratory tract infections
35. Persistence of respiratory syncytial virus (RSV) infection and development of RSV-specific IgG1 response in a guinea-pig model of acute bronchiolitis
36. Persistence of airway hyperresponsiveness and viral antigen following respiratory syncytial virus bronchiolitis in young guinea-pigs
37. Novel pathways in the pathogenesis of respiratory syncytial virus disease
38. Surfactant dysfunction develops in BALB/c mice infected with respiratory syncytial virus
39. Surfactant abnormalities in infants with severe viral bronchiolitis
40. Types of asthma and wheezing
41. Immunity and immunopathology to respiratory syncytial virus. The mouse model
42. Effect of respiratory syncytial virus infection on the uptake of and immune response to other inhaled antigens
43. Anaphylactic sensitisation to aeroallergen during respiratory virus infection
44. Asthma and immunoglobulin E antibodies after respiratory syncytial virus: A prospective cohort study with matched controls
45. Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins
46. Different patterns of cytokine induction in cultures of respiratory syncytial (RS) virus-specific human T-H cell lines following stimulation with RS virus and RS virus proteins
47. Study of 8-year-old children with a history of respiratory syncytial virus bronchiolitis in infancy
48. Wheezing, asthma, and pulmonary dysfunction 10 years after infection with respiratory syncytial virus in infancy
49. Outcome of acute lower respiratory tract infection in infants: Preliminary report of seven-year follow-up study
50. Acute bronchiolitis: Predisposing factors and characterization of infants at risk
51. Respiratory status and allergy nine to 10 yr after acute bronchiolitis
52. Respiratory status and allergy after bronchiolitis
53. Development of an allergen-specific T-cell memory in atopic and normal children
54. Immunologic mechanisms of virus-induced wheezing and asthma
55. Eosinophilia at the time of respiratory syncytial virus bronchiolitis predicts childhood reactive airway disease
56. Nasal cytokine profiles in bronchiolitis and upper respiratory tract infection secondary to respiratory syncytial virus (RSV) infection
57. Cellular immunity is activated and a TH-2 response is associated with early wheezing in infants after bronchiolitis
58. Reduced interferon-gamma production in infants with bronchiolitis and asthma
59. Cellular responses to interferon-gamma
60. Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitisation to allergen
61. Role of interferon gamma in the pathogenesis of primary respiratory syncytial virus infection in BALB/c mice
62. IL-5 and eosinophils are essential for the development of airway hyperresponsiveness following acute respiratory syncytial virus infection
63. Critical roles for interleukin-4 and interleukin-5 during respiratory syncytial virus infection in the development of airway hyperresponsiveness after airway sensitization
64. RSV and chronic asthma
65. Decreased interleukin-12 levels in umbilical cord blood in children who developed acute bronchiolitis
66. Monocyte interleukin-12 production is inversely related to duration of respiratory failure in respiratory syncytial virus bronchiolitis
67. Bronchiolitis
68. Non-immunological exogenous factors modifying bronchial responsiveness
69. Metacholine aerosol as test for bronchial asthma
70. Atopy does not predispose to RSV bronchiolitis or postbronchiolitic wheezing
71. Pulmonary function abnormalities in symptom-free children after bronchiolitis
72. Normal pulmonary function measurements and airway reactivity in childhood after mild bronchiolitis
73. Long-term prospective study in children after respiratory syncytial virus infection
74. The relationship between acute bronchiolitis and childhood asthma
75. The relationship of acute bronchiolitis to bronchial asthma: A 4-14 year follow-up
76. The relationship between proved viral bronchiolitis and subsequent wheezing
77. Wheezing at 8 and 13 years: Changing importance of bronchiolitis and passive smoking
78. Epidemiologic evidence of increased airway reactivity in children with a history of bronchiolitis
79. Long-term effects of respiratory syncytial virus (RSV) bronchiolitis in infants and young children: A quantitative review
80. Recurrent wheezing in children with respiratory syncytial virus (RSV) bronchiolitis in Qatar
81. Bronchopulmonary obstruction in children with respiratory virus infections
82. Characteristics and prognosis of hospital-treated obstructive bronchitis in children aged less than two years
83. Wheezing following lower respiratory tract infections with respiratory syncytial virus and influenza A in infancy
84. Sequelae of respiratory syncytial virus infections. A role for intervention studies
85. Childhood asthma following hospitalization with acute viral bronchiolitis in infancy
86. 2- to 3-year outcome after bronchiolitis
87. Wheezing bronchitis reinvestigated at the age of 10 years
88. Anti-inflammatory therapy reduces wheezing after bronchiolitis
89. Pulmonary function changes in children after respiratory syncytial virus infection in infancy
90. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
91. Long term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo
92. Follow-up of children with respiratory syncytial virus bronchiolitis in 1986 and 1987: Potential effect of ribavirin on long-term pulmonary function
93. Ribavirin Study Group. Prospective follow-up and pulmonary functions from a placebo-controlled randomized trial of ribavirin therapy in respiratory syncytial virus bronchiolitis
94. Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: A preliminary report
95. Prevention strategies for respiratory syncytial virus: Passive and active immunization
96. Respiratory syncytial vaccines
97. A vaccine for RSV: Is it possible?
98. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia
99. Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis
100. Respiratory syncytial virus vaccines: Recent developments
101. Aalderen W.M. Long-term effects of prednisolone in the acute phase of bronchiolitis caused by respiratory syncytial virus
102. Randomised controlled trial of budesonide for the prevention of post-bronchiolitis wheezing
103. One-year follow-up of young children hospitalized for wheezing: The influence of early anti-inflammatory therapy and risk factors for subsequent wheezing and asthma
104. Predictors of asthma three years after hospital admission for wheezing in infancy
105. Inhaled corticosteroids during and after respiratory syncytial virus-bronchiolitis may decrease subsequent asthma
106. Nebulised beclomethasone diproprionate in recurrent obstructive episodes after acute bronchiolitis
107. Inhalation of corticosteroids after hospital care for respiratory syncytial virus infection diminishes development of asthma in infants